Stockscreener 앱 받기
1.88
6.00%
-0.12
시간 외 거래:
1.82
-0.06
-3.19%
전일 마감가:
$2.00
열려 있는:
$1.99
하루 거래량:
95,326
Relative Volume:
3.97
시가총액:
$28.40M
수익:
-
순이익/손실:
$-16.26M
주가수익비율:
-0.8315
EPS:
-2.261
순현금흐름:
$-13.50M
1주 성능:
-8.74%
1개월 성능:
-36.27%
6개월 성능:
-59.74%
1년 성능:
-68.35%
1일 변동 폭
$1.73
$1.9903
1주일 범위
$1.73
$2.095
52주 변동 폭
$1.73
$8.79
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
INTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
1.88 | 28.40M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 - Investing.com
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - Yahoo Finance
Intensity Therapeutics reports positive results of INT230-6 in breast cancer - Yahoo Finance
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Yahoo Finance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - Yahoo Finance
Candel Therapeutics Prostate Cancer Therapy Shows Promise - Yahoo Finance
Candel Therapeutics stock up 172% after Phase III prostate cancer success - Yahoo Finance
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial - Yahoo Finance
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - The Eastern Progress Online
Intensity Therapeutics stock hits 52-week low at $2.46 By Investing.com - Investing.com Canada
Intensity Therapeutics stock hits 52-week low at $2.46 - Investing.com
The Benchmark Company Announces Upcoming Discovery One-on-One Investor Conference - The Manila Times
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit - Yahoo Finance
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy - Yahoo Finance
TG Therapeutics to Participate in the Evercore HealthCONx Conference - Yahoo Finance
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Intensity Therapeutics Selected for Oral Podium Presentation in - GuruFocus.com
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Jeanette Fritsch Expands SIMPLY-HEALTH Platform to Offer Comprehensive Menopause Solutions for Midlife Professionals - Yahoo Finance
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO - AlphaStreet
Intensity Therapeutics secures $3 million in stock offering By Investing.com - Investing.com South Africa
Medical supplies giant Medline reportedly eyeing $5B IPO in 2025 - MSN
Intensity Therapeutics secures $3 million in stock offering - Investing.com India
Shelton-based Intensity Therapeutics gains $3M investment - Hartford Business Journal
H2G Green Limited Launches Major Rights Issue - MSN
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial - Yahoo Finance
Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease - Yahoo Finance
Intensity reports promising sarcoma treatment results - Investing.com
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at - StreetInsider.com
Intensity reports promising sarcoma treatment results By Investing.com - Investing.com UK
Intensity Therapeutics' Cancer Drug Triples Survival Time in Phase 1/2 Sarcoma Trial | INTS Stock News - StockTitan
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - PR Newswire
Corstasis Therapeutics to Present Pivotal Trial Data on Novel Bumetanide Nasal Spray at American Heart Association Scientific Sessions 2024 - Yahoo Finance
Q&A: New cancer medication to treat refractory solid tumours - Digital Journal
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis - Yahoo Finance
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
3 US Penny Stocks With Market Caps Under $200M To Watch - Simply Wall St
Wednesday, November 13, 2024 - The Auto Channel
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke - Yahoo Finance
AstraZeneca Expands U.S. Investment Plan - MSN
Poseida Therapeutics to Present at Two Upcoming Investor Conferences - Yahoo Finance
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting - The Malaysian Reserve
Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting - Yahoo Finance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - Quantisnow
Stem Cell Therapy Market Analysis Report 2024-2029: iPSC Technology and Personalized Medicine Trends Drive Growth - Yahoo Finance
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - The Manila Times
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):